A Liposome Encapsulated Ruthenium Polypyridine Complex As a Theranostic Platform for Triple-Negative Breast Cancer

Overview

Journal Nano Lett

Publisher American Chemical Society

Specialty Biotechnology

Date 2017 Apr 19

PMID 28418672

Citations 32

Authors

Jianliang Shen

Han-Cheon Kim

Joy Wolfram

Chaofeng Mu

Wei Zhang

Haoran Liu

Yan Xie

Junhua Mai

Hang Zhang

Zhi Li

Maria Guevara

Zong-Wan Mao

Haifa Shen

Affiliations

Soon will be listed here.

Abstract

Ruthenium coordination complexes have the potential to serve as novel theranostic agents for cancer. However, a major limitation in their clinical implementation is effective tumor accumulation. In this study, we have developed a liposome-based theranostic nanodelivery system for [Ru(phen)dppz](ClO) (Lipo-Ru). This ruthenium polypyridine complex emits a strong fluorescent signal when incorporated in the hydrophobic lipid bilayer of the delivery vehicle or in the DNA helix, enabling visualization of the therapeutic agent in tumor tissues. Incubation of MDA-MB-231 breast cancer cells with Lipo-Ru induced double-strand DNA breaks and triggers apoptosis. In a mouse model of triple-negative breast cancer, treatment with Lipo-Ru dramatically reduced tumor growth. Biodistribution studies of Lipo-Ru revealed that more than 20% of the injected dose accumulated in the tumor. These results suggest that Lipo-Ru could serve as a promising theranostic platform for cancer.

Citing Articles

2-Guanidinobenzimidazole as Ligand in Supramolecular, Coordination and Organometallic Chemistry.

Padilla-Martinez I, Cruz A, Garcia-Baez E Int J Mol Sci. 2025; 26(3).

PMID: 39940830 PMC: 11817364. DOI: 10.3390/ijms26031063.

A state-of-the-art review of the recent advances of theranostic liposome hybrid nanoparticles in cancer treatment and diagnosis.

Azimizonuzi H, Ghayourvahdat A, Ahmed M, Kareem R, Jaber Zrzor A, Mansoor A Cancer Cell Int. 2025; 25(1):26.

PMID: 39871316 PMC: 11773959. DOI: 10.1186/s12935-024-03610-z.

GSH/pH-responsive copper-based cascade nanocomplexes inducing immunogenic cell death through cuproptosis/ferroptosis/necroptosis in oral squamous cell carcinoma.

Sun Y, Li E, Zhong W, Deng Z, Zhou Z, Wong K Mater Today Bio. 2025; 30():101434.

PMID: 39839490 PMC: 11750277. DOI: 10.1016/j.mtbio.2024.101434.

Role of Radiology in the Diagnosis and Treatment of Breast Cancer in Women: A Comprehensive Review.

Arslan M, Asim M, Sattar H, Khan A, Thoppil Ali F, Zehra M Cureus. 2024; 16(9):e70097.

PMID: 39449897 PMC: 11500669. DOI: 10.7759/cureus.70097.

Liposomal Formulations of Metallodrugs for Cancer Therapy.

Botter E, Caligiuri I, Rizzolio F, Visentin F, Scattolin T Int J Mol Sci. 2024; 25(17).

PMID: 39273286 PMC: 11394711. DOI: 10.3390/ijms25179337.

References

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View

Teng Y, Thike A, Wong N, Tan P . Therapeutic targets in triple negative breast cancer - where are we now?. Recent Pat Anticancer Drug Discov. 2011; 6(2):196-209. DOI: 10.2174/157489211795328521. View

Fang J, Nakamura H, Maeda H . The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2010; 63(3):136-51. DOI: 10.1016/j.addr.2010.04.009. View

Berkovich E, Monnat Jr R, Kastan M . Roles of ATM and NBS1 in chromatin structure modulation and DNA double-strand break repair. Nat Cell Biol. 2007; 9(6):683-90. DOI: 10.1038/ncb1599. View

Khalid A, Persano S, Shen H, Zhao Y, Blanco E, Ferrari M . Strategies for improving drug delivery: nanocarriers and microenvironmental priming. Expert Opin Drug Deliv. 2016; 14(7):865-877. PMC: 5584706. DOI: 10.1080/17425247.2017.1243527. View

Fulda S, Debatin K . Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006; 25(34):4798-811. DOI: 10.1038/sj.onc.1209608. View

Shen J, Xu R, Mai J, Kim H, Guo X, Qin G . High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics. ACS Nano. 2013; 7(11):9867-80. PMC: 3868485. DOI: 10.1021/nn4035316. View

Boeuf G, Roullin G, Moreau J, Van Gulick L, Zambrano Pineda N, Terryn C . Encapsulated Ruthenium(II) Complexes in Biocompatible Poly(d,l-lactide-co-glycolide) Nanoparticles for Application in Photodynamic Therapy. Chempluschem. 2020; 79(1):171-180. DOI: 10.1002/cplu.201300242. View

Shen J, Kim H, Mu C, Gentile E, Mai J, Wolfram J . Multifunctional gold nanorods for siRNA gene silencing and photothermal therapy. Adv Healthc Mater. 2014; 3(10):1629-37. PMC: 4182177. DOI: 10.1002/adhm.201400103. View

10.

Clarke M, Zhu F, Frasca D . Non-platinum chemotherapeutic metallopharmaceuticals. Chem Rev. 2001; 99(9):2511-34. DOI: 10.1021/cr9804238. View

11.

Pasut G, Paolino D, Celia C, Mero A, Joseph A, Wolfram J . Polyethylene glycol (PEG)-dendron phospholipids as innovative constructs for the preparation of super stealth liposomes for anticancer therapy. J Control Release. 2014; 199:106-13. DOI: 10.1016/j.jconrel.2014.12.008. View

12.

Florea A, Busselberg D . Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel). 2013; 3(1):1351-71. PMC: 3756417. DOI: 10.3390/cancers3011351. View

13.

Paolino D, Cosco D, Gaspari M, Celano M, Wolfram J, Voce P . Targeting the thyroid gland with thyroid-stimulating hormone (TSH)-nanoliposomes. Biomaterials. 2014; 35(25):7101-9. DOI: 10.1016/j.biomaterials.2014.04.088. View

14.

Shen J, Kim H, Su H, Wang F, Wolfram J, Kirui D . Cyclodextrin and polyethylenimine functionalized mesoporous silica nanoparticles for delivery of siRNA cancer therapeutics. Theranostics. 2014; 4(5):487-97. PMC: 3966054. DOI: 10.7150/thno.8263. View

15.

Parvani J, Gujrati M, Mack M, Schiemann W, Lu Z . Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer. Cancer Res. 2015; 75(11):2316-2325. PMC: 4452414. DOI: 10.1158/0008-5472.CAN-14-3485. View

16.

Wolfram J, Suri K, Yang Y, Shen J, Celia C, Fresta M . Shrinkage of pegylated and non-pegylated liposomes in serum. Colloids Surf B Biointerfaces. 2013; 114:294-300. PMC: 3884810. DOI: 10.1016/j.colsurfb.2013.10.009. View

17.

Puckett C, Barton J . Methods to explore cellular uptake of ruthenium complexes. J Am Chem Soc. 2007; 129(1):46-7. PMC: 2747593. DOI: 10.1021/ja0677564. View

18.

Rajeswaran A, Trojan A, Burnand B, Giannelli M . Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of.... Lung Cancer. 2007; 59(1):1-11. DOI: 10.1016/j.lungcan.2007.07.012. View

19.

Brabec V, Novakova O . DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity. Drug Resist Updat. 2006; 9(3):111-22. DOI: 10.1016/j.drup.2006.05.002. View

20.

Tan L, Shen J, Liu J, Zeng L, Jin L, Weng C . Spectral characteristics, DNA-binding and cytotoxicity of two functional Ru(II) mixed-ligand complexes. Dalton Trans. 2012; 41(15):4575-87. DOI: 10.1039/c2dt12402e. View